Form D · Biotechnology

Phi Therapeutics, Inc.

Petaluma, CA · CIK 0001778492

Offering snapshot reported Jun 26, 2024 · SEC filing

Reported sold: $7.66M
Investors reported: 22
Minimum accepted: $10K
First sale: Mar 22, 2023

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$4,155,831 → $7,655,830
Reported investors16 → 22

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jun 26, 2024	Amendment	$7,655,830	$3,499,999vs Apr 6, 2023	22	SEC filing
Apr 6, 2023	Initial	$4,155,831	No comparison	16	SEC filing
Jan 6, 2022	Initial	$660,000	No comparison	7	SEC filing
Jun 4, 2019	Initial	$575,000	No comparison	4	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-478065

Includes the conversion of certain convertible promissory notes

Source: Form D, filed Jun 26, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Maria Cho	Director, Promoter
Neil Giugno	Director, Executive
Kevin Law	Director
Jun Li	Director
Yug Varma	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1250 Petaluma Blvd N
Petaluma, CA, 94952